SCHEMBL21639174

SCHEMBL21639174

CC(C)(C)OC(=O)N[C@@H](Cc1ccc(NC(=O)CNC(=O)CNC(=O)OCC2c3ccccc3-c3ccccc32)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 1/20 0.51
▸ PABPC1 P11940 1/20 0.49
▸ ACE P12821 1/20 0.48
▸ ITGB3 P05106 1/20 0.46
▸ ITGB1 P05556 1/20 0.46
▸ ITGAV P06756 1/20 0.46
▸ ITGA2B P08514 1/20 0.46
▸ ITGB5 P18084 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.45
▸ CTSS P25774 3/20 0.43
▸ CTSK P43235 2/20 0.43
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ MDM4 O15151 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ATM Q13315 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21639175 1.00 MDM2 (0.51) MDM2PABPC1ACEITGB3ITGB1
SCHEMBL21639288 0.98 MDM2 (0.52) MDM2PABPC1ACEITGB3ITGB1
SCHEMBL21639290 0.98 MDM2 (0.52) MDM2PABPC1ACEITGB3ITGB1
SCHEMBL29529271 0.94 PABPC1 (0.48) MDM2PABPC1ACEHDAC8CTSS
SCHEMBL29529423 0.92 PABPC1 (0.49) MDM2PABPC1ACEHDAC8CTSS
SCHEMBL2249260 0.90 MDM2 (0.58) MDM2ACEITGB3ITGB1ITGAV
SCHEMBL503172 0.90 MDM2 (0.58) MDM2ACEITGB3ITGB1ITGAV
SCHEMBL371161 0.90 MDM2 (0.58) MDM2ACEITGB3ITGB1ITGAV
SCHEMBL14039181 0.88 MDM2 (0.62) MDM2ACEITGB3ITGB1ITGAV
SCHEMBL29445607 0.88 MDM2 (0.62) MDM2ACEITGB3ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 — — US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 — — US disclosed
EP-3604326-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM Corporation (JP) 2020-02-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 MDM2 4758/4885PABPC1 1638/4885ACE 1959/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 MDM2 4758/4885PABPC1 1638/4885ACE 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback